| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shirin Arjmandi-Rad, John D Vestergaard Nieland, Kathryn G Goozee, Salar Vasegh. The effects of different acetylcholinesterase inhibitors on EEG patterns in patients with Alzheimer's disease: A systematic review. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2023-10-16. PMID:37843690. |
the effects of different acetylcholinesterase inhibitors on eeg patterns in patients with alzheimer's disease: a systematic review. |
2023-10-16 |
2023-11-08 |
Not clear |
| Modesto de Candia, Alexander A Titov, Antonio Viayna, Larisa N Kulikova, Rosa Purgatorio, Brigida Piergiovanni, Mauro Niso, Marco Catto, Leonid G Voskressensky, F Javier Luque, Cosimo D Altomar. In-vitro and in-silico studies of annelated 1,4,7,8-tetrahydroazocine ester derivatives as nanomolar selective inhibitors of human butyrylcholinesterase. Chemico-biological interactions. 2023-10-15. PMID:37839515. |
based on previous finding showing 2,3,6,11-tetrahydro-1h-azocino[4,5-b]indole as suitable scaffold of novel inhibitors of acetylcholinesterase (ache), a main target of drugs for the treatment alzheimer disease and related dementias, herein we investigated diverse newly and previously synthesized β-enamino esters (and ketones) derivatives of 1,4,7,8-tetrahydroazocines (and some azonines) fused with benzene, 1h-indole, 4h-chromen-4-one and pyrimidin-4(3h)-one. |
2023-10-15 |
2023-11-08 |
human |
| Ivan M Veselov, Daria V Vinogradova, Andrey V Maltsev, Pavel N Shevtsov, Elena A Spirkova, Sergey O Bachurin, Elena F Shevtsov. Mitochondria and Oxidative Stress as a Link between Alzheimer's Disease and Diabetes Mellitus. International journal of molecular sciences. vol 24. issue 19. 2023-10-14. PMID:37833898. |
it is important to note that drugs used to treat alzheimer's disease, in particular acetylcholinesterase inhibitors, show a positive therapeutic potential in the treatment of type 2 diabetes, while drugs used in the treatment of type 2 diabetes can also prevent a number of pathologies characteristic for alzheimer's disease. |
2023-10-14 |
2023-10-15 |
Not clear |
| Qi Jia, Pei-Yuan Yang, Xin Zhang, Shao-Jiang Song, Xiao-Xiao Huan. Aromatic glycosides and lignans glycosides with their acetylcholinesterase inhibitory activities from the leaves of Picrasma quassioides. Fitoterapia. 2023-10-13. PMID:37832877. |
cholinesterase inhibitors are often used as alzheimer's disease inhibitors.thus, acetylcholinesterase and butyrylcholinesterase inhibitory activity of these eight compounds were tested, and results showed that only compound 6 showed weakly acetylcholinesterase inhibitory activity. |
2023-10-13 |
2023-10-15 |
Not clear |
| Roxanne Vasquez, Leonardo Batista, Teobaldo Cuy. Computational Study on the Enzyme-Ligand Relationship between Cannabis Phytochemicals and Human Acetylcholinesterase: Implications in Alzheimer's Disease. The journal of physical chemistry. B. 2023-10-10. PMID:37815196. |
computational study on the enzyme-ligand relationship between cannabis phytochemicals and human acetylcholinesterase: implications in alzheimer's disease. |
2023-10-10 |
2023-10-15 |
human |
| Rani Sasidharan, Ratheesh Mohanan, Neelima Kukreti, Praveen Raj, Mohamed A Abdelgawad, Mohammed M Ghoneim, Sreedharannair L Manju, Bijo Mathe. MAO-B Inhibitor (2E)-3-(4-Bromophenyl)-1-(1H-indol-3-yl) prop-2-en-1-one as a Neuroprotective Agent Against Alzheimer's Disease. Neurochemical research. 2023-10-09. PMID:37814132. |
considering the importance of chalcones as monoamine oxidase and acetylcholinesterase inhibitors, the study was designed as a comprehensive and systematic analysis to evaluate the pharmacological activities leading to the formation of drug molecules against alzheimer's disease (ad). |
2023-10-09 |
2023-10-15 |
Not clear |
| Wenli Shi, Wenxin Han, Yijing Liao, Jiaqi Wen, Guowen Zhan. Inhibition mechanism of fisetin on acetylcholinesterase and its synergistic effect with galantamine. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. vol 305. 2023-09-28. PMID:37769468. |
the search for acetylcholinesterase (ache) inhibitors produced by natural sources is of great significance for the prevention and therapy of alzheimer's disease and has been widely concerned. |
2023-09-28 |
2023-10-07 |
Not clear |
| Seongmin Park, Mingeun Kim, Yuxi Lin, Mannkyu Hong, Geewoo Nam, Adam Mieczkowski, József Kardos, Young-Ho Lee, Mi Hee Li. Designing multi-target-directed flavonoids: a strategic approach to Alzheimer's disease. Chemical science. vol 14. issue 35. 2023-09-15. PMID:37712013. |
the underlying causes of alzheimer's disease (ad) remain a mystery, with multiple pathological components, including oxidative stress, acetylcholinesterase, amyloid-β, and metal ions, all playing a role. |
2023-09-15 |
2023-10-07 |
Not clear |
| Manickam Rajkumar, Sundarraj Navaneethakrishnan, Sundarapandian Muthukumar, Ramasundaram Thangaraj, Magudeeswaran Sivanandam, Karuppaiya Vimala, Soundarapandian Kanna. Gelatin/polyethylene glycol-loaded magnesium hydroxide nanocomposite to attenuate acetylcholinesterase, neurotoxicity, and activation of GPR55 protein in rat models of Alzheimer's disease. Journal of chemical neuroanatomy. 2023-09-14. PMID:37708946. |
gelatin/polyethylene glycol-loaded magnesium hydroxide nanocomposite to attenuate acetylcholinesterase, neurotoxicity, and activation of gpr55 protein in rat models of alzheimer's disease. |
2023-09-14 |
2023-10-07 |
rat |
| Nadine Bittner, Cleo S M Funk, Alexander Schmidt, Felix Bermpohl, Eva J Brandl, Engi E A Algharably, Reinhold Kreutz, Thomas G Rieme. Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis. Drugs & aging. 2023-09-08. PMID:37682445. |
psychiatric adverse events of acetylcholinesterase inhibitors in alzheimer's disease and parkinson's dementia: systematic review and meta-analysis. |
2023-09-08 |
2023-10-07 |
Not clear |
| Somaia S Abd El-Karim, Manal M Anwar, Nesreen S Ahmed, Yasmin M Syam, Samia A Elseginy, Hanan F Aly, Eman A Younis, Wagdy K B Khalil, Kawkab A Ahmed, Faten F Mohammed, Maha Riz. Discovery of novel benzofuran-based derivatives as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease: Design, synthesis, biological evaluation, molecular docking and 3D-QSAR investigation. European journal of medicinal chemistry. vol 260. 2023-09-07. PMID:37678141. |
discovery of novel benzofuran-based derivatives as acetylcholinesterase inhibitors for the treatment of alzheimer's disease: design, synthesis, biological evaluation, molecular docking and 3d-qsar investigation. |
2023-09-07 |
2023-10-07 |
Not clear |
| Shraddha Manish Gupta, Ashok Behera, Neetesh K Jain, Avanish Tripathi, Dinesh Rishipathak, Siddharth Singh, Nafees Ahemad, Meryem Erol, Devendra Kuma. Development of substituted benzylidene derivatives as novel dual cholinesterase inhibitors for Alzheimer's treatment. RSC advances. vol 13. issue 38. 2023-09-06. PMID:37671344. |
leading pathological markers of alzheimer's disease (ad) include acetylcholinesterase (ache), butyrylcholinesterase (buche), amyloid beta (aβ) and reactive oxygen species (ros). |
2023-09-06 |
2023-10-07 |
human |
| Nandhini Subramanian, Brittany Watson, Chen-Zhong Li, Melissa Moss, Chang Li. Patterning amyloid-β aggregation under the effect of acetylcholinesterase using a biological nanopore - an Sensors and actuators reports. vol 6. 2023-09-04. PMID:37663321. |
patterning amyloid-β aggregation under the effect of acetylcholinesterase using a biological nanopore - an aggregation of amyloid-β peptide (aβ) is hypothesized to be the primary cause of alzheimer's disease (ad) progression. |
2023-09-04 |
2023-09-07 |
Not clear |
| Moulay Ahfid El Alaouy, Marwa Alaqarbeh, Mohamed Ouabane, Hanane Zaki, Mohamed ElBouhi, Hassan Badaoui, Youness Moukhliss, Abdelouahid Sbai, Hamid Maghat, Tahar Lakhlifi, Mohammed Bouachrin. Computational Prediction of 3,5-Diaryl-1H-Pyrazole and spiropyrazolines derivatives as potential acetylcholinesterase inhibitors for alzheimer disease treatment by 3D-QSAR, molecular docking, molecular dynamics simulation, and ADME-Tox. Journal of biomolecular structure & dynamics. 2023-09-01. PMID:37655700. |
computational prediction of 3,5-diaryl-1h-pyrazole and spiropyrazolines derivatives as potential acetylcholinesterase inhibitors for alzheimer disease treatment by 3d-qsar, molecular docking, molecular dynamics simulation, and adme-tox. |
2023-09-01 |
2023-09-07 |
Not clear |
| Abdullah A Elgazar, Ramadan A El-Domany, Wagdy M Eldehna, Farid A Badri. Theophylline-based hybrids as acetylcholinesterase inhibitors endowed with anti-inflammatory activity: synthesis, bioevaluation, RSC advances. vol 13. issue 36. 2023-08-31. PMID:37649576. |
theophylline-based hybrids as acetylcholinesterase inhibitors endowed with anti-inflammatory activity: synthesis, bioevaluation, in this study, we investigated the conjugation of theophylline with different compounds of natural origin hoping to construct new hybrids with dual activity against cholinergic and inflammatory pathways as potential agents for the treatment of alzheimer's disease (ad). |
2023-08-31 |
2023-09-07 |
Not clear |
| Javier Avendaño-Godoy, Arnoldo Miranda, Sigrid Mennickent, Carolina Gómez-Gaet. Intramuscularly Administered PLGA Microparticles for Sustained Release of Rivastigmine: In Vitro, In Vivo and Histological Evaluation. Journal of pharmaceutical sciences. 2023-08-26. PMID:37595752. |
rivastigmine is an acetylcholinesterase (ache) and butyrylcholinesterase (bche) inhibitor drug approved by the us food and drug administration (fda) for the treatment of mild to moderate dementia of alzheimer's type. |
2023-08-26 |
2023-09-07 |
rat |
| Luciana R Tallini, Camila Rockenbach da Silva, Tatiana Jung, Elen de Oliveira Alves, Samira Leila Baldin, Miriam Apel, Luis F S M Timmers, Eduardo Pacheco Rico, Jaume Bastida, José Angelo S Zuanazz. Acetylcholinesterase Inhibition Activity of Life (Basel, Switzerland). vol 13. issue 8. 2023-08-26. PMID:37629578. |
galanthamine, the most relevant one, has been commercialized for the palliative treatment of alzheimer's disease symptoms since 2001 due to its potential as an acetylcholinesterase (ache) inhibitor. |
2023-08-26 |
2023-09-07 |
Not clear |
| Mariana G Fronza, Diego Alves, Domenico Praticò, Lucielli Savegnag. The neurobiology and therapeutic potential of multi-targeting β-secretase, glycogen synthase kinase 3β and acetylcholinesterase in Alzheimer's disease. Ageing research reviews. vol 90. 2023-08-24. PMID:37595640. |
the neurobiology and therapeutic potential of multi-targeting β-secretase, glycogen synthase kinase 3β and acetylcholinesterase in alzheimer's disease. |
2023-08-24 |
2023-09-07 |
Not clear |
| Pratibha Sharma, Varinder Singh, Manjinder Sing. N-methylpiperazinyl and piperdinylalkyl-O-chalcone derivatives as potential polyfunctional agents against Alzheimer's disease: Design, synthesis and biological evaluation. Chemical biology & drug design. 2023-08-20. PMID:37599098. |
the series of n-methylpiperazinyl and piperdinylalkyl-o-chalcone derivatives as potential polyfuctional agents against alzheimer's disease that have been designed, synthesized and then evaluated biologically using in vitro assays for the inhibition of acetylcholinesterase (ache) activity, ages, and free radical formation. |
2023-08-20 |
2023-09-07 |
Not clear |
| Hanan A Abd Elmonem, Reham M Morsi, Doaa S Mansour, El-Sayed R El-Saye. Myco-fabricated ZnO nanoparticles ameliorate neurotoxicity in mice model of Alzheimer's disease via acetylcholinesterase inhibition and oxidative stress reduction. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine. 2023-08-09. PMID:37556014. |
myco-fabricated zno nanoparticles ameliorate neurotoxicity in mice model of alzheimer's disease via acetylcholinesterase inhibition and oxidative stress reduction. |
2023-08-09 |
2023-08-16 |
mouse |